IBRX241220P4500
- 0.29
- +0.04+16.00%
ImmunityBio Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds
Catalyst Watch: Robotaxi IPO, OPEC+, Holiday Shopping Data, and Movie Blockbusters
ImmunityBio And NCartes Enter Collaboration Agreement Aimed At Automating And Streamlining The Data Fulfillment Process For Clinical Trials; The Goal Of The Collaboration Is To Make This Essential Process Easier, Faster, And Less Expensive For...
Express News | Immunitybio and Ncartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
ImmunityBio and NCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Sector Update: Health Care
ImmunityBio Shares Rise After 'Significant' Update on Bladder Cancer Treatment
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment Of The 100th Patient In BCG Unresponsive NMIBC CIS Trial And Reports A Complete Response Rate Of 71% With A Durable Duration Of Response Ranging Up To 54 Months Reported For 82 Patients...
Express News | Immunitybio Inc - Data to Be Submitted to EMA in Q4 2024
Express News | Immunitybio Completes Anktiva’s Post-Approval Enrollment of the 100TH Patient in Bcg Unresponsive Nmibc CIS Trial and Reports a Complete Response Rate of 71% With a Durable Duration of Response Ranging up to 54 Months
ImmunityBio Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. D.Boral Maintained a Buy Rating on the Stock.
ImmunityBio | 8-K: ImmunityBio Reports Third-Quarter 2024 Financial Results
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
ImmunityBio Analyst Ratings
ImmunityBio | 10-Q: Q3 2024 Earnings Report
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
Express News | Immunitybio Inc Q3 Shr View $-0.18 -- LSEG IBES Data
ImmunityBio 3Q Loss $85.8M >IBRX